Patent 12023331 was granted and assigned to Intra-Cellular Therapies on July, 2024 by the United States Patent and Trademark Office.
The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT